Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.88 USD 0.00% Intraday chart for Regulus Therapeutics Inc. +3.60% +125.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target MT
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors CI
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating MT
Top Midday Gainers MT
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell MT
Transcript : Regulus Therapeutics Inc. - Special Call
Top Premarket Gainers MT
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease CI
Regulus Therapeutics Inc. announced that it expects to receive $100.000267 million in funding from a group of investors CI
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease CI
Transcript : Regulus Therapeutics Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 10:25 AM
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Top Premarket Decliners MT
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease CI
Canaccord Genuity Raises Regulus Therapeutics' Price Target to $12 From $9, Keeps Buy Rating MT
Transcript : Regulus Therapeutics Inc. - Special Call
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease CI
Transcript : Regulus Therapeutics Inc. - Special Call
Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease CI
Regulus Therapeutics Inc. Appoints Preston S. Klassen to the Board CI
Chart Regulus Therapeutics Inc.
More charts
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.88 USD
Average target price
7.25 USD
Spread / Average Target
+151.74%
Consensus